Today, obesity is the most important modi®able risk factor for type 2 diabetes. An excess of body fat is associated with a deterioration of glucose utilisation and promotes the development of type 2 diabetes, particularly in those with a genetic predisposition for the disease. It is also well established that a reduction of excess body fat improves insulin sensitivity and can prevent the conversion to diabetes. In those with overt diabetes, weight loss usually ameliorates glycaemic control and associated metabolic disturbances. Among the pharmacological agents that are used for the treatment of type 2 diabetes only metformin has a weak weight-lowering activity and is considered as the drug of choice for adjunct pharmacotherapy in obese diabetic subjects. A few studies also suggest that acarbose can induce a modest weight reduction in such patients. In contrast, sulphonylurea and insulin treatment is frequently accompanied by substantial weight gain which should be taken into consideration when these drugs are used. Another approach to improve metabolic control in obese type 2 diabetic patients is the use of weight-lowering agents. The new serotonin and noradrenaline reuptake inhibitor sibutramine promotes weight loss which subsequently leads to improved glycaemic control. Orlistat, a lipase inhibitor, is also able to ameliorate metabolic control in such patients due to its weight-lowering potential. As obesity remains a therapeutic challenge in most type 2 diabetic subjects, weight management drugs may represent an alternative or supplement to antidiabetic agents. Moreover, weight management agents have the advantage that they have additional favourable effects on associated cardiovascular risk factors.
Introduction
Type 2 diabetes is the most common form of disorders of carbohydrate metabolism and affects approximately 5% of the general population in Europe. Although type 2 diabetes is a heterogeneous disease, it is characterised by two main defects: impaired secretion of insulin and reduced insulin sensitivity. Irrespective of the fact that the molecular mechanisms underlying the disease are only incompletely understood, the current view is that type 2 diabetes results from a genetically programmed failure of the endocrine pancreas to compensate for insulin resistance. 1 There is general agreement that obesity plays a pivotal role in the pathogenesis of type 2 diabetes. Overwhelming evidence from prospective epidemiological studies indicates that the risk of developing diabetes strongly depends on body weight and that weight loss reduces this risk. Two recent studies, the Nurses' Health Study for women and the Physicians' Health Study for men, con®rmed this association and added the ®nding that weight change closely modulates this risk. 2, 3 It is noteworthy from the results of these studies that the risk of clinical diabetes increases substantially already in the upper level of normal weight and at moderate levels of overweight. At a BMI between 24 and 24.9 kgam 2 the relative risk of developing type 2 diabetes in middle-aged women during the 14 y observation period was 5.0 compared with women with a BMI less than 22 kgam 2 . Women with a BMI of 31 kgam 2 or more had an age-adjusted relative risk of 40 or greater. The majority of new cases were in the overweight category. It is also important to note that weight loss since the age of 18 was associated with a decreased incidence of diabetes. 2 Similar ®ndings concerning weight change and the risk of diabetes were made in men. 3 We recently reported that the mean BMI of newly detected type 2 diabetic subjects, calculated from self-reported weight and measured height, was 29.9 kgam 2 . 4 However, it should be kept in mind that only between 30 and 50% of all obese individuals will develop diabetes or impaired glucose tolerance representing mainly those with a genetic predisposition.
The mechanisms which may explain the close relationship between excess body weight and type 2 diabetes are not clear. It is well known that obesity induces a decrease in insulin sensitivity which may be a useful adaptive mechanism to prevent further weight gain. 5 At present, there are several hypotheses concerning the mechanisms of action responsible, including elevated free fatty acids, tumour necrosis factor-a (TNF-a) and, more recently, leptin. 6 ± 9 A clinically important observation is that type 2 diabetes preferentially develops in those with an abdominal pattern of fat distribution emphasising the special role of the visceral fat depot for the unfavourable metabolic consequences of obesity. 6 In the obese diabetic patient one of the initial management targets is to achieve weight loss by dietary means. 10 However, the success rate of strategies to change dietary habits and physical activity is disappointing. The rate of primary dietary failure in newly detected type 2 diabetic subjects (de®ned as fasting blood glucose b 15 mmolal or persistent symptoms of hyperglycaemia) is approximately 15% within the ®rst 3 months according to the UKPDS (United Kingdom Prospective Diabetes Study) data set. 11 In order to obtain satisfactory metabolic control, an adjunct treatment with oral antidiabetic agents or insulin must be considered in the majority of patients. For this purpose, several pharmacological agents to lower blood glucose are currently available (Table 1) . The aim of this review is, ®rstly, to discuss the impact of these antidiabetic agents on body weight and, secondly, to deal with the effect of weight management drugs on glycaemic control in obese diabetic patients.
Antidiabetic drugs
Numerous clinical studies have demonstrated the bene®cial effect of currently approved antidiabetic agents on short-term metabolic variables such as elevated blood glucose and glycated haemoglobin levels. In the recently published UKPDS, intensive blood glucose control by either insulin or sulphonylureas substantially decreased the risk of microvascular complications, but not macrovascular disease. 12 Metformin used as an additional treatment mode in obese patients showed a greater risk reduction for any diabetes-related endpoints than insulin or sulphonylureas. 13 As the mechanisms of action differ between these agents, combination strategies have been successfully established. A common observation during the use of these drugs is that they directly or indirectly improve insulin sensitivity which may per se increase the risk of further weight gain. One explanation for this phenomenon may be that the loss of energy in the form of glucose in the urine is reduced or abolished by improved insulin action. Others may include an increase in appetite and an increased caloric intake in the case of hypoglycaemia, for example under insulin therapy.
Sulphonylureas
Sulphonylureas are the most widely used oral blood glucose lowering agents. They stimulate insulin secretion from the pancreatic b-cells by interacting with speci®c receptors to close ATP-dependent K -channels. As a consequence, circulating insulin concentrations are elevated both in the basal and postprandial state, at least during the ®rst months of treatment. Due to the improved responsiveness of the b-cells to glucose upon sulphonylurea treatment, there is also an amelioration of insulin sensitivity which may then lead to a secondary fall in insulin concentrations. 14 It has long been known that the use of these antidiabetic agents is associated with signi®cant weight gain. It was reported in a recent analysis of the UKPDS data that type 2 diabetic subjects who were randomly assigned to treatment by sulphonylureas gained on average 5.3 kg in the primary diet failure group and 4.9 kg in the main randomisation group, respectively, over a 6-year observation period. 11 Although it is unclear how this weight gain affects metabolic control, this is an undesired effect as the increase in body weight may worsen diabetic control per se and, in addition, may also worsen other risk factors.
Metformin
Metformin is known to lower blood glucose by inhibiting hepatic glucose production and by increasing insulin sensitivity in peripheral tissues. Other weaker effects include delayed intestinal glucose absorption and a decrease in blood lipids. In addition, metformin has a weak anorectic action which may favour weight loss. However, the potential to promote weight reduction is rather limited. In clinical trials, metformin monotherapy induced a weight loss of between 1 and 3% of initial weight. 15 In a recent multicentre trial, metformin treatment decreased body weight by up to 3.8 kg over 29 weeks. 16 In the UKPDS, those obese subjects who were randomly assigned to metformin therapy had an average decrease in body weight of 1.3 kg in the primary diet failure group over a 6 y period, which was signi®cantly different from the weight gain in those diabetic subjects receiving either sulphonylureas or insulin. 11 Moreover, metformin has bene®cial effects on other components of the metabolic syndrome and was recently found to reduce insulin resistance and induce ovulation in women with the polycystic ovary syndrome. 17 Due to these favourable effects in addition to that on body weight metformin is regarded as the drug of choice in overweight type 2 diabetic patients. 10 However, because of potential serious side effects the many contraindications to metformin treatment must be carefully considered. Acarbose belongs to the class of a-glucosidase inhibitors which have been introduced into the treatment of type 2 diabetes a few years ago. Inhibition of these enzymes in the intestine delays carbohydrate absorption and reduces the postprandial rise in blood glucose. In some, but not all, clinical trials, long-term use of acarbose was reported to result in modest weight loss. 18, 19 In a recent randomised, placebo-controlled study over 12 months, obese type 2 diabetic subjects on acarbose therapy lost on average 0.46 kg, which differed signi®cantly from the weight gain of 0.33 kg in the placebo group. 19 The mechanisms responsible for this effect are unclear. In the study by Wolever et al, no effect of acarbose on energy and nutrient intake or dietary pattern was observed. 19 However, one plausible explanation may be the small energy loss due to increased carbohydrate fermentation in the colon, as the energy obtained from carbohydrates which are fermented in the colon is estimated to be only 50% of that obtained from carbohydrates absorbed from the intestine. 20 The current view is that this modest weight reduction is not clinically signi®cant, but may represent a small advantage compared to other antidiabetic drugs which increase body weight.
Insulin
Insulin exerts a variety of anabolic effects in the body. Insulin stimulates glucose transport into muscle and fat cells and inhibits lipolysis. Insulin is also responsible for lipogenesis from carbohydrates and favours adipose tissue growth. Clinical experience and controlled trials suggest that weight gain is a frequent consequence of initiating insulin therapy in diabetic patients for multiple reasons, for example recurrent episodes of hypoglycaemia may require additional carbohydrate intake to elevate blood glucose levels. In the UKPDS, a marked weight gain was seen in the type 2 diabetic patients treated with insulin. In the primary diet failure group, the mean increase in body weight under insulin therapy over 6 y was 9.9 kg with an even greater increase of 10.4 kg in the obese subjects. The patients in the main randomisation group who were initially allocated to insulin exhibited a mean increase in body weight of 7.8 kg. 11 The insulin-treated patients had signi®cantly more hypoglycaemic events than the patients under treatment by oral antidiabetic drugs. The authors of the study concluded that it may not be advantageous to start directly with insulin therapy even in type 2 diabetic patients with primary dietary failure. In addition, it should also be stressed that diabetic subjects under insulin treatment may have particular dif®culties in reducing body weight if they are obese.
Thiazolidinediones
This new class of insulin-sensitising agents is currently being introduced into diabetes management in many countries. 21 These compounds are known to be ligands of a speci®c nuclear receptor, the so called peroxisome-proliferator-activated receptor g2 (PPAR g2), which plays a crucial role in gene expression in adipose tissue and possibly other organs. These agents are also potent inducers of the recruitment of adipocyte precursor cells and thereby of adipose tissue growth, as activation of PPAR g2 is one of the key molecular steps that initiates this process. 22 Clinical studies clearly demonstrated that these drugs have the potential to reduce elevated blood glucose levels, particularly in early phases of the disease process. However, one has to keep in mind that weight increase can only occur when there is a long-term positive energy balance. As these drugs apparently do not affect energy intake or expenditure, they may not promote weight gain per se, but long-term studies on this aspect are missing and desirable.
Recent developments
Currently, many new compounds with potential glucose lowering action are in development. For example, glucagon-like peptide 1 (GLP-1) and GLP-1 analogues such as GLP-1 (7-36) or GLP-1 (7-36 amide) have been reported to ameliorate glycaemic control by delaying gastric emptying, lowering glucagon concentrations, stimulating insulin secretion and by enhancing insulin sensitivity, thereby opposing many characteristic disturbances in type 2 diabetes. In addition, GLP-1 has been found to reduce body weight by a possibly central appetite-suppressing mechanism. 23 
Weight management agents and their potential in the management of type 2 diabetes
The rationale for a pharmacological approach in the management of obesity is the low success rate of conventional non-pharmacological strategies. Failure of dietary, behavioural and exercise therapy is common, which prompted early attempts to develop speci®c drugs for weight reduction. However, previous experience with drug therapy is rather con¯ict-ing. Only very recently, the centrally acting drugs fen¯uramine and dexfen¯uramine were withdrawn from the market after reports of serious heart valve abnormalities in obese patients under treatment with these agents. 24 For this reason, the results of clinical trials using these compounds with respect to the treatment of obese type 2 diabetic subjects will be only brie¯y reviewed. Emphasis will be given to new agents with more promising results in clinical studies ( Table 2) .
The group of centrally acting agents can be split into two groups. The ®rst group is the large group of 25 The many possible adverse effects such as addictive potential, risk of primary pulmonary hypertension and cardiovascular complications no longer justify their clinical application in obese individuals. The second group comprises the non-stimulatory serotoninergic agents such as dexfenuramine and¯uoxetine.
Serotoninergic agents
Fen¯uramine (a releaser of serotonin) was originally approved for the treatment of obese patients. Early studies had demonstrated that addition of fen¯uramine to a diabetes diet not only reduces body weight but also improves glycaemic control and blood lipids. 26 ± 28 Dexfen¯uramine is the biologically active dextrostereoisomer of the racemic compound fen¯uramine and has been reported to have fewer adverse effects and to induce weight loss. 29 Dexfen¯uramine has been shown in human studies to cause both reduced hepatic glucose production and improved peripheral glucose uptake when given acutely. 30 When administered to type 2 diabetic patients for weeks or months, dexfenuramine improves metabolic control, reduces insulin requirement and has favourable effects on other risk factors. 31 Another study demonstrated that dexfen¯ur-amine preferentially reduces abdominal fat and, therefore, may have a special potential in the treatment of obese subjects with the metabolic syndrome. 32 However, due to possible serious adverse effects on heart valves, fen¯uramine and dexfen¯uramine were withdrawn in 1997. 24 Fluoxetine selectively inhibits the central reuptake of serotonin and is widely used as an antidepressant drug. Fluoxetine also has anorectic properties that can promote a moderate weight loss. In obese type 2 diabetic subjects,¯uoxetine has been found to improve glycaemic control, 33 but its application for this indication is not allowed in most countries.
A number of new drugs to support weight management are under development. Two interesting new compounds are currently approved in some countries as an adjunct treatment in the management of obesity.
Sibutramine
Sibutramine is a recently developed selective serotonin and noradrenaline reuptake inhibitor. Blocking of serotonin reuptake may explain the satiety enhancing effect of the drug, whereas inhibition of noradrenaline uptake may mainly cause an increase in thermogenesis via b 3 -adrenoceptors and, thereby, in energy expenditure. In randomised controlled clinical trials, sibutramine produced a dose-related weight reduction. At 10 ± 15 mg per day weight loss under sibutramine was 3 ± 6 kg greater than under placebo and this effect was maintained for up to 52 weeks. 34 In a study of 91 obese patients with type 2 diabetes, it was recently observed that treatment with 15 mg sibutramine daily for 12 weeks induced an additional weight loss which was associated with a small improvement in HbA lc levels ( 7 0.4 vs 0 %, P`0.01). 35 In a hyperinsulinaemic euglycaemic clamp study, sibutramine administration for 12 weeks resulted not only in a greater reduction of HbA 1c and fructosamine in type 2 diabetic subjects compared to controls but also in an signi®cant improvement in the oxidative and nonoxidative glucose disposal rate. 36 
Orlistat
Orlistat is a speci®c inhibitor of gastric and pancreatic lipases which reduces the absorption of dietary triglycerides from the gastrointestinal tract. 37 In combination with a low-fat and moderately energy-restricted diet, orlistat was found to reduce body weight by 10.3 kg in obese men and women compared to 6.1 kg in the age-and weight-matched placebo group over a 1-y treatment period. In the second year of the study, those who continued with orlistat had a smaller weight regain than those who were switched to placebo treatment. 38 In a 1 y randomised controlled trial in obese subjects with type 2 diabetes, orlistat treatment in addition to a mildly hypocaloric diet resulted in a 6.2 kg weight loss compared to 4.3 kg in the placebo group. There was an improvement in HbA 1c concentrations ( 7 0.28 vs 0.18%, P`0.001) and a dose reduction of oral sulphonylurea medication ( 7 23 vs 7 9%, P`0.002) as well as an improvement in the lipid pro®le, suggesting that orlistat is an effective adjunct treatment in obese patients with type 2 diabetes. 39 
Other weight-lowering drugs
The ®rst attempts to use b 3 -adrenoceptor agonists for weight reduction were made more than 10 years ago. Previous animal experiments had demonstrated that selective b 3 -agonists can induce weight loss and exhibit a weight-independent favourable effect on insulin resistance and glucose intolerance. However, subsequent studies in humans were disappointing as only very small effects were seen. 40 The explanation for this discrepancy may be that the compounds used in these studies were not selective for the human b 3 -adrenergic receptor. 41 Therefore, many new Moderately positive.
Impact of pharmacotherapy on weight management H Hauner S15 b 3 -agonists are currently under development with a higher selectivity for humans and it will be interesting to see whether these new compounds will also have a positive effect on insulin resistance in man. Leptin is a recently discovered adipocyte-derived hormone which is released into the circulation and acts as a satiety signal in the brain. 42 The results of the ®rst clinical study in humans suggest that subcutaneous administration of a biosynthetic leptin reduces body weight in humans in a dose-dependent manner, almost exclusively due to a loss of body fat. At the highest concentration used, a weight reduction of 7.5% was achieved as compared to 1.7% in the placebo group over a 6-month treatment period 43 suggesting that leptin and possibly leptin analogues have a weight-reducing potential also in hyperleptinaemic obese subjects.
Some current open questions
The appropriate de®nition of patients who will bene®t most from the use of weight management agents will become an important issue in the near future. Concerning type 2 diabetes, it must be kept in mind that the majority of patients are over the age of 65. With increasing age, there is a physiological decrease in body weight due to an age-dependent reduction in food intake or sometimes almost complete loss of appetite. We have recently observed that type 2 diabetic subjects over the age of 72 y have a lower mean BMI as compared to those under 72 years of age (27.5 kgam 2 vs 29.8 kgam 2 , P`0.01). Concomitantly, the mean fasting blood glucose and mean HbA 1c levels were signi®cantly lower in the older group, probably due to the lower weight and lower caloric intake. 44 At this age, the risk of nutritional de®cits probably outweighs the risk of overnutrition. Therefore, it should be stressed that only type 2 diabetic patients of younger age should be considered for weight management agents and may have a positive bene®tarisk ratio.
Another issue is the role of associated risk factors and complications as possible contraindications for the use of weight management agents. Type 2 diabetes is frequently accompanied by hypertension and sibutramine can increase blood pressure by 2 ± 3 mmHg on average. Therefore blood pressure should be carefully monitored on initiation and therapy discontinued if there is a signi®cant increase in blood pressure. In the long run, weight loss by sibutramine is associated with a net decrease in blood pressure. A possible limitation of treatment with orlistat is the reduction of serum levels of fat-soluble vitamins and b-carotene. In addition, as many patients with type 2 diabetes may suffer from autonomic neuropathy of the gastrointestinal tract, it is unknown how these patients will react to this drug.
In conclusion, among the currently used antidiabetic drugs, sulphonylureas and insulin induce a signi®cant increase in body weight, whereas metformin and acarbose have either no effect or induce a modest weight reduction which makes the latter two the ®rst-line drugs in obese patients. Agents which are able to lower body weight per se, such as sibutramine and orlistat, have bene®cial effects on glycaemic control and other associated risk factors such as dyslipidaemia and hypertension and may represent an effective alternative or adjunct treatment to conventional antidiabetic drugs, particularly in younger obese patients with the metabolic syndrome. However, further clinical studies are required to better determine the role of these new drugs for weight management in obese subjects with type 2 diabetes.
